Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657215 | 1.00 | KMT2A (0.41) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2669507 | 1.00 | KMT2A (0.41) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2655879 | 0.95 | KMT2A (0.43) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2655875 | 0.95 | KMT2A (0.43) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2656466 | 0.90 | PPARA (0.45) | PPARAPPARGPPARDALDH1A1LMNA | |
| SCHEMBL2656463 | 0.90 | PPARA (0.45) | PPARAPPARGPPARDALDH1A1LMNA | |
| SCHEMBL2656641 | 0.90 | PPARA (0.38) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2656643 | 0.90 | PPARA (0.38) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2657826 | 0.89 | PPARA (0.39) | KMT2APPARAPPARGPPARDCDK2 | |
| SCHEMBL2657828 | 0.89 | PPARA (0.39) | KMT2APPARAPPARGPPARDCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | claimed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | claimed |
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KMT2A 2713/4885PPARA 1441/4885PPARG 623/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KMT2A 2713/4885PPARA 1441/4885PPARG 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.